Ubs Asset Management Americas Inc Summit Therapeutics Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
199Shares Held
76MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$580 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$260 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$188 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$129 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$82.4 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.78B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...